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Reports of Oct4 expression in somatic and cancer cells have suggested that Oct4 could regulate
self-renewal in somatic stem cells as it does in embryonic stem cells. In this issue of Cell Stem
Cell, Lengner et al. (2007) provide compelling evidence that Oct4 is neither expressed in nor required
for somatic stem cell function.It is said that ‘‘absence of evidence is
not evidence of absence,’’ or stated
another way, ‘‘one cannot prove a neg-
ative.’’ These adages remind us how
difficult it is to demonstrate with a high
degree of certainty that a phenomenon
does not occur, compared to finding
evidence that a phenomenon does
occur. Even well-designed experi-
ments providing evidence that condi-
tion ‘‘X’’ has no measurable effect on
‘‘Y’’ might not be considered ‘‘signifi-
cant’’ contributions by reviewers, sci-
entific editors, or the scientists them-
selves. Consequently, there is a good
chance that ‘‘negative’’ results are
underreported, ultimately leading to
the accumulation of bias toward ‘‘pos-
itive’’ results. However, when such re-
sults address an important (and con-
tentious) hypothesis, it is imperative
that they be made known. This is the
case for the work of Lengner et al.
(2007), who addressed the question of
whether Oct4 plays a role in somatic
stem cell function.
Oct4 is well known as a regulator of
gene expression in embryonic stem (ES)
cells and plays a critical role in self-
renewal and pluripotency in the inner
cell mass and epiblast of the embryo;
after terminal differentiation, Oct4 ex-
pression is strongly repressed. Intrigu-
ingly, a number of publications have
reported Oct4 expression in somatic
and tumor cell types either by PCR-
based methods or through detection
of an Oct4 antigen in tissues or cell
lysates. These observations raised the
controversial hypothesis that Oct4
could play a role in somatic stem cellsanalogous to its role in ES cells and
thus serve as a general marker of
pluripotency. Lengner and colleagues
tested this hypothesis with inducible
tissue-specific Cre-mediated ablation
of Oct4, quantitative RT-PCR (qRT-
PCR), and a transgenic Oct4-IRES-
EGFP reporter, showing that Oct4 is
dispensable for tissue homeostasis,
regeneration, and somatic stem cell
self-renewal.
Given the previous reports of Oct4
expression in somatic cells, deter-
mining the level of endogenous Oct4
expression in somatic stem cells was
critical. qRT-PCR studies consistently
show the same result: endogenous
Oct4 transcript levels from somatic
cells are equivalent to background,
and more importantly, any detectable
expression is several orders of magni-
tude lower than is found in ES cells.
One potential caveat is that most so-
matic stem cells are difficult to define
and/or purify; measuring transcript
abundance can therefore be problem-
atic if the transcript of interest is
expressed in a rare population of stem
cellswithin acomplex tissue.However,
the authors fractionated tissues in or-
der to enrich for stem cells, perhaps
most convincingly in the intestinal epi-
thelium and hematopoietic system, in
order to demonstrate essentially unde-
tectable Oct4 expression in somatic
cells. Furthermore, the level of tran-
script detected after selective Cre-
mediated deletion of Oct4 (see below)
was similar to the level detected in
tissues from nonrecombined control
animals, raising the distinct possibilityCell Stem Cell 1that the low-level Oct4 expression
observed in somatic tissues—in the
current study as well as in previous re-
ports—could simply represent a false
positive result due to background
noise in PCR or spurious amplification
from an Oct4 pseudogene. This con-
clusion is supported by the results of
Liedtke et al. (2007), also in this issue
of Cell Stem Cell, who show PCR de-
tection of human Oct4 in cord blood
and peripheral blood mononuclear
cells that was likely due to genomic
DNA contamination and amplifica-
tion of Oct4 retropseudogenes. They
demonstrate that this artifact can be
prevented by rigorous selection of
primers, highlighting the importance
of stringent primer design in order to
avoid false-positive PCR products.
Lengner et al. (2007) also used an
Oct4-IRES-EGFP reporter knocked-
in to the endogenous Oct4 locus to
examine expression. Fluorescence-
activated cell sorting (FACS) confirmed
that the Oct4 locus was active in virtu-
ally all of the ES cells. However, when
bone marrow was obtained from mice
derived from these ES cells, no EGFP
expression was observed, even when
hematopoietic progenitors (c-Kit+,
Sca-1+, Lineage) were analyzed.
These data, combined with qRT-PCR
and negative immunohistochemistry
results, provide compelling evidence
that Oct4 is not expressed in somatic
stem cells, consistent with the conclu-
sion that Oct4 is completely silenced
during differentiation.
The primary goal of the manuscript
was to addresswhetherOct4 functions, October 2007 ª2007 Elsevier Inc. 359
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question, Lengner and colleagues
utilized a strain of mice in which the
endogenous Oct4 locus was targeted
by loxP sites. When crossed with
various strains harboring different
inducible and/or tissue-specific Cre
recombinase (Villin-CreER, Keratin15-
CrePr1, Mx1-Cre, and Nestin-Cre),
the Oct4 locus was selectively deleted
and thus somatic cell function could
be examined in the absence of Oct4.
The resulting data indicated normal
steady-state tissue homeostasis in
the intestine, bone marrow, and skin
after tissue-specific ablation of Oct4,
and normal proliferative and differenti-
ation capacity of mesenchymal stem
cells tested in vitro. Oct4 ablation in
the CNS resulted in no gross mor-
phological or behavioral abnormali-
ties. In addition, there was normal
regenerative capacity in Oct4 null
intestine after irradiation, normal he-
matopoietic reconstitution after trans-
plantation of Oct4 deleted bone mar-
row into lethally irradiated recipients,
normal liver regeneration after partial
hepatectomy in the absence of Oct4,
and normal healing of full-thickness
dermal punches in Oct4 null skin.
A key issue in evaluating the implica-
tions of these data is whether the
experiments themselves are designed
in such a way as to provide ironclad
evidence for truly normal stem cell
function in the absence of Oct4. In
a way, this question goes to the heart
of what defines a somatic stem cell:
multipotency and self-renewal. For
any given tissue, what precise aspect
of stem cell function does a given as-
say test? What are the gold-standard
assays for demonstrating defects in
stem cell multipotency or self-re-
newal? In the hematopoietic system,
successful engraftment and multiline-360 Cell Stem Cell 1, October 2007 ª200age reconstitution after bone marrow
transplantation is considered to be ev-
idence for normal stem cell function.
However, for other tissues the gold-
standard assays are not as well
defined. Nevertheless, the overall im-
pression of these results is that abla-
tion of Oct4 in somatic tissues yields
no detectable effect on homeostasis
or short-term regeneration and that
the function of Oct4 in somatic stem
cells, if any, is therefore minimal.
Although Lengner et al. (2007) have
provided strong evidence against
a role for Oct4 in somatic cells, it is for-
mally possible that Oct4 has functions
in somatic lineages or stem cells that
were not directly tested in the experi-
ments performed. It is also possible
that the transgenic Cre recombinase
was not expressed in the stem cells
of a given tissue but only in their prog-
eny. Furthermore, the present results
do not rule out the possibility that
Oct4 reactivation could play a role in
oncogenesis. Despite these caveats,
it appears that the use of Oct4 expres-
sion as a surrogate marker for somatic
stem cells is of dubious value. This
finding reinforces the conclusion that
there may be no universal stem cell
signature (Burns and Zon, 2002) and
that attempts to apply stem cell
markers from one system ubiqui-
tously, such has now been tried with
Oct4, CD34, Sca-1, and others, may
be misguided. In the face of the care-
fully designed and thorough study of
Lengner and colleagues, it is our opin-
ion that the onus is now upon those
who propose a function for endoge-
nousOct4 in somatic stem cells to pro-
vide definitive evidence in favor of this
hypothesis.
In a broader context, the contro-
versy over Oct4 in somatic cells under-
scores the importance of publishing7 Elsevier Inc.definitive positive or negative data.
Despite the difficulty of ‘‘proving a neg-
ative,’’ we have recently seen a spate
of high-profile papers refuting claims
with substantial clinical implications,
such as the contribution of bone
marrow cells to replenishment of car-
diomyocytes (Orlic et al., 2001; Murry
et al., 2004; Balsam et al., 2004) and
oocytes (Johnson et al., 2005; Eggan
et al., 2006). These disputes presumably
reflect ‘‘irrational exuberance’’ in a field
with high stakes for researchers, funding
and publishing entities, as well as pa-
tients, perhaps indicating the need to
increase the standards for ‘‘proof’’ of
positive results to the same extent as
we expect for ‘‘proof’’ of negative
results.
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